Eli Lilly's Trading Volume Drops 51.52% to 22nd Place Despite Stock Price Gains and Promising Cancer Drug Trial Results

On June 2, 2025, Eli Lilly and Company (LLY) experienced a significant decline in trading volume, with a total of 21.82 billion shares traded, marking a 51.52% decrease from the previous day. This placed Eli Lilly at the 22nd position in terms of trading volume for the day. Meanwhile, Eli Lilly's stock price increased by 1.28%, marking the third consecutive day of gains and a total increase of 3.85% over the past three days.

Eli Lilly and Company recently announced encouraging Phase 1 trial results for its investigational antibody-drug conjugate (ADC), LY4170156, designed to treat ovarian cancer. The study evaluated the drug's safety, pharmacokinetics, and anti-tumor activity, revealing an overall response rate (ORR) of 45% among 58 patients assessed for efficacy. Notably, the drug demonstrated efficacy across various dose levels and folate receptor alpha (FRα) expression levels, including in patients previously treated with mirvetuximab soravtansine.

The trial, which enrolled 95 participants with high-grade serous ovarian cancer, showed that the drug was effective at all dose levels, regardless of FRα expression. The most common side effects included nausea, anemia, fatigue, vomiting, diarrhea, and neutropenia. No treatment-emergent neuropathy or ocular toxicity was observed, and no maximum tolerated dose has been established.

These positive results suggest that LY4170156 has the potential to improve outcomes for women with advanced ovarian cancer, particularly those who have not responded to previous treatments. The data was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the drug's promising safety and anti-tumor activity profile.